Atara Biotherapeutics, Inc.
- Jurisdiction
United States - LEI
549300WBXUXZRE03MS38 - ISIN
US0465132068 (ATRA )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
6
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. Read full profile
Stock price
Fundamentals
- Net revenue
€162.55M - Gross margin
81.2% - EBIT
€6.93M - EBIT margin
4.3% - Net income
€4.99M - Net margin
3.1%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Dividends
No dividend payouts
Insider Transactions
| Name | Title | Transaction Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Grant-Huerta Yanina | Chief Accounting Officer |
|
|
|
|
| Nguyen AnhCo | President and CEO |
|
|
|
|
| Huang James | N/A |
|
|
|
|
Earnings Calls
Latest earnings call: November 4, 2023
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Sell |